Pular para o conteúdo principal
Ranking Invest

GYRE - Gyre Therapeutics, Inc.

Segmento: HealthcareGyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Análise Ranking Invest

Valor de Mercado
$ 692.40 Mi
IVR
-0.01Índice proprietário de comparação relativa: -0,01.
IVR2
-0.13Leitura proprietária complementar: -13%.
MLL
-0.13Leitura proprietária complementar: -13%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 73.37 Mi

Dívida Líquida

-$ 43.29 Mi

L4T

-$ 19.56 Mi

MM4T

-19.26%

Indicadores Básicos

ROE

-26.66%

Índices de Previsibilidade

Receita Líquida

D0.10

Lucro

F2.30

Margem

F2.58

Índices de Tendência

Receita Líquida

D1.37

Lucro

D1.44

Margem

C1.53

Índices de Endividamento

DIV/PAT

-0.59

DIV/L4T

2.21

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.